In support of the in vitro data, the Siglec-4 spacer CAR displayed a similar anti-tumor efficacy in vivo as the cognate CD8α spacer CAR against TSPAN8 and both therapies were superior to the IgG4-based spacer CAR treatment. This evidence concerns the gene CD8A and neoplasm.